Beranda › Kanker Paru Sel Kecil › Florida › Orlando
Uji klinis Kanker Paru Sel Kecil di Orlando, FL
15 studi untuk Kanker Paru Sel Kecil mencari peserta di lokasi sekitar Orlando (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Advent Health, Orlando
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- AdventHealth Cancer Institute, Orlando
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Menerima pesertaFase 3
- Orlando Health Cancer Institute /ID# 280418, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Menerima pesertaFase 1
- Sara Cannon Research Institute Lake Nona, Orlando
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Menerima pesertaFase 3
- University of Florida Health Cancer Center at Orlando Health, Orlando
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Menerima pesertaFase 3
- Clermont Oncology Center, Clermont · 24 mi jauhnya
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Menerima pesertaFase 1/2
- Avenzo Therapeutics Recruiting Site, Orlando
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Menerima pesertaFase 2
- Clermont Oncology Center, Clermont · 24 mi jauhnya
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- AdventHealth Celebration, Celebration · 17 mi jauhnya
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Menerima pesertaFase 3
- AdventHealth Orlando, Cancer Institute, Orlando
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Menerima pesertaFase 1
- Florida Cancer Specialists, Orlando
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Study of LY4175408 in Participants With Advanced Cancer
Menerima pesertaFase 1
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi jauhnya
Uji klinis Kanker Paru Sel Kecil di kota lain
- Houston, TX26 studi
- Arlington, VA23 studi
- Boston, MA21 studi
- New York City, NY21 studi
- Nashville, TN20 studi
- Los Angeles, CA20 studi
- Dallas, TX13 studi
- St. Louis, MO13 studi
- Cleveland, OH13 studi
- Detroit, MI12 studi
- Chicago, IL12 studi
- Washington, DC12 studi
Studi lain di Orlando
- Kanker Paru Non-Sel Kecil44 studi
- Obesitas31 studi
- Kanker Metastatik29 studi
- Kelebihan Berat Badan27 studi
- Penyakit Alzheimer25 studi
- Diabetes Tipe 224 studi
- Kanker (semua jenis)24 studi
- Kanker Payudara23 studi
- Kanker Ovarium22 studi
- Kolitis Ulseratif22 studi
- Kanker Paru21 studi
- Kanker Kolorektal19 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.